🔬 A New Hope in the Fight Against Cancer
A groundbreaking test known as Galleri, developed by U.S. biotech company Grail, has shown stunning results — identifying more than 50 types of cancer from a single blood sample.
In a study of over 25,000 adults across North America, scientists found that Galleri could detect cancer signals even in people with no current screening options, including ovarian, liver, bladder, and pancreatic cancers.🩸 Revolutionary Blood Test Detects Over 50 Cancers Early — A Game Changer for Global Health
🧬 How the Test Works
The Galleri test identifies tiny fragments of tumor DNA that circulate in the blood.
These fragments serve as molecular clues, revealing not just the presence but even the origin of the cancer in 9 out of 10 positive cases.
More than half of the detected cancers were caught at early stages, when treatment success is most likely.
📊 Accuracy That Could Save Millions
The test correctly ruled out cancer in over 99% of negative cases, reducing false alarms.
When combined with traditional screenings for breast, lung, bowel, and cervical cancers, Galleri boosted total detection rates by seven times.
“This could be transformative,” said Dr. Nima Nabavizadeh of Oregon Health & Science University.
“It changes how doctors approach cancer prevention and early diagnosis.”
🏥 Trials and Global Reach
The UK’s National Health Service (NHS) is currently testing Galleri on 140,000 participants, with early results expected next year.
If proven successful, the program could expand to over one million people, making mass early cancer detection a global reality.
“Most people die because cancer is found too late,” said Sir Harpal Kumar of Grail.
“We aim to change that by catching it early — when treatment still works.”
⚖️ Caution and Next Steps
Experts urge caution until long-term data confirms whether early detection truly reduces deaths.
Professor Clare Turnbull of the Institute of Cancer Research explained:
“It’s an exciting leap forward, but we must prove it translates into saved lives.”
🌍 The Bigger Picture
If validated, Galleri could revolutionize cancer screening worldwide, especially in regions where medical infrastructure is weak.
It could mark the start of a future where a single blood test can save millions through early and accurate detection.